A new macromolecular paramagnetic MR contrast agent binds to activated human platelets

Contrast Media and Molecular Imaging

Volumn 2, Issue 4, 2007, Pages 178-188

  Chaubet, Fréderic ^a,f   Bertholon, Isabelle ^a,f   Serfaty, Jean Michel ^a,b,f   Bazeli, Ramin ^a,b,f   Alsaid, Hasan ^c,g   Jandrot Perrus, Martine ^a,f   Zahir, Charaf ^a,f   Even, Pascale ^d   Bachelet, Laure ^a,f   Touat, Ziad ^a,f   Lancelot, Eric ^e   Corot, Claire ^e   Canet Soulas, Emmanuelle ^c,g   Letourneur, Didier ^a,f  

^a INSERM   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CNRS   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e Laboratoire Guerbet   (France)

^f UNIVERSITÉ PARIS 13   (France)

^g UNIVERSITÉ LYON 1   (France)

Author keywords

Activated platelets; Atherosclerosis; Contrast agent; Flow cytometry; Gadolinium; Magnetic resonance imaging

Indexed keywords

CARBOXYL GROUP; CARBOXYMETHYLDEXTRAN; CARBOXYMETHYLDEXTRAN 1; CARBOXYMETHYLDEXTRAN 8; DEXTRAN DERIVATIVE; GADOTERIC ACID; GADOTERIC ACID CARBOXYMETHYLDEXTRAN; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; P SELECTIN GLYCOPROTEIN LIGAND 1; SULFATE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ANEURYSM; ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYDRODYNAMICS; IN VITRO STUDY; MACROMOLECULE; MOLECULAR IMAGING; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIODIAGNOSIS; SULFATION; THROMBOCYTE ACTIVATION;

BLOOD PLATELETS; CONTRAST MEDIA; ELECTRON SPIN RESONANCE SPECTROSCOPY; HETEROCYCLIC COMPOUNDS; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR MIMICRY; ORGANOMETALLIC COMPOUNDS; PLATELET ACTIVATION;

EID: 35148887221     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.144     Document Type: Article

References (46)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001:systematic analysis of population health data. Lancet 2006; 9524: 1747-1757.
2. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 21 (suppl. 1): II2-10.
3. Libby P. Inflammation in atherosclerosis. Nature 2002; 6917: 868-874.
4. Kerwin W, Hooker A, Spilker M, Vicini P, Ferguson M, Hatsukami T, Yuan C. Quantitative magnetic resonance imaging analysis of neovasculature volume in carotid atherosclerotic plaque. Circulation 2003; 6: 851-856.
5. Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, Mizsei G, Chereshnev I, Fallon JT, Reis E, Fuster V, Toussaint JF, Fayad ZA. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. Atherosclerosis 2005; 1: 79-85.
6. Boutry S, Burtea C, Laurent S, Toubeau G, Vander Elst L, Muller RN. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent. Magn. Reson. Med. 2005; 4: 800-807.
7. Corot C, Perry KG, Trivedi R, Saleh A, Jonkmanns C, Le Bas JF, Blezer E, Rausch M, Brochet B, Foster-Gareau P, Baleriaux D, Gaillard S, Dousset V. Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest. Radiol. 2004; 10: 619-625.
8. Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents. Eur. J. Radiol. 2003; 1: 33-44.
9. Yu X, Song SK, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. Magn. Reson. Med. 2000; 6: 867-872.
10. Ross R. Atherosclerosis is an inflammatory disease. Am. Heart J. 1999; 5 (Pt 2): S419-420.
11. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb. Haemost. 2001; 3: 746-756.
12. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J. Clin. Invest. 2005; 12: 3378-3384.
13. Wagner DD. New links between inflammation and thrombosis. Arterioscler. Thromb. Vasc. Biol. 2005; 7: 1321-1324.
14. Sirol M, Fuster V, Badimon JJ, Fallon JT, Moreno PR, Toussaint JF, Fayad ZA. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. Circulation 2005; 11: 1594-1600.
15. McEver RP. Selectin-carbohydrate interactions during inflammation and metastasis. Glycoconj. J. 1997; 5: 585-591.
16. Lasky LA. Selectin-carbohydrate interactions and the initiation of the inflammatory response. A. Rev. Biochem. 1995; 113-139.
17. Ihrcke NS, Wrenshall LE, Lindman BJ, Platt JL. Role of heparan sulfate in immune system-blood vessel interactions. Immunol. Today 1993; 10: 500-505.
18. Blondin C, Bataille I, Letourneur D. Polysaccharides for vascular cell targeting. Crit. Rev. Ther. Drug Carrier Syst. 2000; 4: 327-375.
19. Vestweber D, Blanks JE. Mechanisms that regulate the function of the selectins and their ligands. Physiol. Rev. 1999; 1: 181-213.
20. Ramphal JY, Zheng ZL, Perez C, Walker LE, DeFrees SA, Gaeta FC. Structure-activity relationships of sialyl Lewis x-containing oligosaccharides. 1. Effect of modifications of the fucose moiety. J. Med. Chem. 1994; 21: 3459-3463.
21. Brandley BK, Kiso M, Abbas S, Nikrad P, Srivasatava O, Foxall C, Oda Y, Hasegawa A. Structure-function studies on selectin carbohydrate ligands. Modifications to fucose, sialic acid and sulphate as a sialic acid replacement. Glycobiology 1993; 6: 633-641.
22. Hiramatsu Y, Tsujishita H, Kondo H. Studies on selectin blocker. 3. Investigation of the carbohydrate ligand sialyl Lewis X recognition site of P-selectin. J. Med. Chem. 1996; 23: 4547-4553.
23. Chaubet F, Huynh R, Champion J, Jozefonvicz J, Letourneur D. Sulfated polysaccharides derived from dextran: biomaterial for vascular therapy. Polym. Int. 1999; 48: 313-319.
24. Maïga-Revel O, Chaubet F, Jozefonvicz J. New investigations on heparin-like derivatized dextrans: CMDBS, synergistic role of benzylamide and sulfate substituents in anticoagulant activity. Carbohydr. Polym. 1997; 32: 89-93.
25. Corot C, Schaefer M, Beaute S, Bourrinet P, Zehaf S, Benize V, Sabatou M, Meyer D. Physical, chemical and biological evaluations of CMD-A2-Gd-DOTA. A new paramagnetic dextran polymer. Acta Radiol. Suppl. 1997; 91-99.
26. Chaabane L, Pellet N, Bourdillon MC, Desbleds Mansard C, Sulaiman A, Hadour G, Thivolet-Bejui F, Roy P, Briguet A, Douek P, Canet Soulas E. Contrast enhancement in atherosclerosis development in a mouse model: in vivo results at 2 Tesla. Magma 2004; 3-6: 188-195.
27. Canet EP, Casali C, Desenfant A, An MY, Corot C, Obadia JF, Revel D, Janier MF. Kinetic characterization of CMD-A2-Gd-DOTA as an intravascular contrast agent for myocardial perfusion measurement with MRI. Magn. Reson. Med. 2000; 3: 403-409.
28. Huynh R, Chanbet F, Jozefonvicz J. Anticoagulant properties of dextranmethylcarboxylate benzylamide sulfate (DMCBSu); a new generation of bioactive functionalized dextran. Carbohydr. Res. 2001; 1: 75-83.
29. Huynh VD, Chaubet F, Jozefonvicz J. Carboxymethylation of dextran in aqueous/alcohol mixture as the first step of preparation of CMDBS derivatized dextrans. Angew. Makromol. Chem. 1998; 254: 61-65.
30. Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami TS, Yuan C. Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler. Thromb. Vasc. Biol. 2005; 1: 234-239.
31. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002; 11: 1368-1373.
32. Yuan C, Mitsumori LM, Ferguson MS, Polissar NL, Echelard D, Ortiz G, Small R, Davies JW, Kerwin WS, Hatsukami TS. In vivo accuracy of multispectral magnetic resonance imaging for identifying lipid-rich necrotic cores and intraplaque hemorrhage in advanced human carotid plaques. Circulation 2001; 17: 2051-2056.
33. Fayad ZA, Nahar T, Fallon JT, Goldman M, Aguinaldo JG, Badimon JJ, Shinnar M, Chesebro JH, Fuster V. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: a comparison with transesophageal echocardiography. Circulation 2000; 21: 2503-2509.
34. Summers RM, Andrasko-Bourgeois J, Feuerstein IM, Hill SC, Jones EC, Busse MK, Wise B, Bove KE, Rishforth BA, Tucker E, Spray TL, Hoeg JM. Evaluation of the aortic root by MRI: insights from patients with homozygous familial hypercholesterolemia. Circulation 1998; 6: 509-518.
35. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. Circulation 1996; 5: 932-938.
36. Wilensky RL, Song HK, Ferrari VA. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. J. Am. Coll. Cardiol. 2006; (8 Suppl): C48-56.
37. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 2003; 18: 2270-2274.
38. Lanza GM, Winter P, Caruthers S, Schmeider A, Crowder K, Morawski A, Zhang H, Scott MJ, Wickline SA. Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr. Pharm. Biotechnol. 2004; 6: 495-507.
39. Bottrill M, Kwok L, Long NJ. Lanthanides in magnetic resonance imaging. Chem. Soc. Rev. 2006; 6: 557-571.
40. da Costa Martins P, Garcia-Vallejo JJ, van Thienen JV, Fernandez-Borja M, van Gils JM, Beckers C, Horrevoets AJ, Hordijk PL, Zwaginga JJ. P-selectin glycoprotein ligand-1 is expressed on endothelial cells and mediates monocyte adhesion to activated endothelium. Arterioscler. Thromb. Vasc. Biol. 2007; 5: 1023-1029.
41. Chaubet F, Canet-Soulas E, Chaabane L, Zahir C, Brigger I, Corot C, Letourneur D. A new contrast agent for magnetic resonance imaging of the vascular walls. Contrast Med. Mol. Imaging 2006; 2: 62.
42. Varki A. Selectin ligands. Proc. Natl. Acad. Sci. U S A 1994; 16: 7390-7397.
43. Pochechueva TV, Ushakova NA, Preobrazhenskaya ME, Nifantiev NE, Tsvetkov YE, Sablina MA, Tuzikov AB, Bird MI, Rieben R, Bovin NV. P-selectin blocking potency of multimeric tyrosine sulfates in vitro and in vivo. Bioorg. Med. Chem. Lett. 2003; 10: 1709-1712.
44. Eklund A. On the determination of available lysine in casein and rapeseed protein concentrates using 2,4,6-trinitrobenzenesulphonic acid (TNBS) as a reagent for free epsilon amino group of lysine. Anal. Biochem. 1976; 2: 434-439.
45. Jandrot-Perrus M, Didry D, Guillin MC, Nurden AT. Cross-linking of alpha and gamma-thrombin to distinct binding sites on human platelets. Eur. J. Biochem. 1988; 2: 359-367.
46. Linden MD, Frelinger AL 3rd, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin. Thromb. Hemost. 2004; 5: 501-511.